Badrising, Sushil <br/><br/>
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.  [electronic resource] 

 -  Cancer  Apr 2014 
 - 968-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.28518  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Androstenes<br/>Androstenols--therapeutic use<br/>Antineoplastic Agents--adverse effects<br/>Benzamides<br/>Docetaxel<br/>Humans<br/>Male<br/>Middle Aged<br/>Nitriles<br/>Phenylthiohydantoin--adverse effects<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Survival Analysis<br/>Taxoids--therapeutic use<br/>Treatment Outcome